Diseases /
Thyroid Gland Papillary Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries. Diagnostic procedures include thyroid ultrasound and fine needle biopsy. Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance. [1]
Thyroid gland papillary carcinomas most frequently harbor alterations in BRAF, NRAS, RET, TP53, and ATM [2].
BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, BRAF V600E, and NRAS Mutation are the most common alterations in thyroid gland papillary carcinoma [2].
Biomarker-Directed Therapies
Clinical Trials
Significant Genes in Thyroid Gland Papillary Carcinoma
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.